8-K Announcements
6Material company update
Mar 17, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Mar 10, 2026·SEC
Harvard Bioscience, Inc.(HBIO)Earnings, Financials & Key Ratios
HBIO•NASDAQ
$7.24
$324M mkt cap·Price updated May 6, 2026
AboutHarvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.Show more
- Revenue$87M-8.1%
- EBITDA$5M+589.5%
- Net Income-$57M-357.1%
- EPS (Diluted)-1.28-357.1%
- Gross Margin53.01%-8.9%
- EBITDA Margin6.14%+650.0%
- Operating Margin-0.73%+89.0%
- Net Margin-65.51%-397.1%
- ROE-147.13%-709.0%
- ROIC-0.65%+84.9%
- Debt/Equity2.61+271.8%
- Interest Coverage-0.13+93.4%
HBIO Key Insights
Harvard Bioscience, Inc. (HBIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Efficient asset utilization: 1.1x turnover
✗Weaknesses
- ✗High debt to equity ratio of 2.6x
- ✗Expensive at 23.4x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
HBIO Price & Volume
Harvard Bioscience, Inc. (HBIO) stock price & volume — 10-year historical chart
Loading chart...
HBIO Growth Metrics
Harvard Bioscience, Inc. (HBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-2.25%
5 Years-3.25%
3 Years-8.6%
TTM-8.06%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-357.07%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-347.16%
Return on Capital
10 Years-1.19%
5 Years-2%
3 Years-2.05%
Last Year-0.97%
HBIO Recent Earnings
Harvard Bioscience, Inc. (HBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
Mar 12, 2026EPS
$0.01
Est $0.35
-102.9%
Revenue
$24M
Est $23M
+2.7%
Q4 2025
Nov 6, 2025EPS
$0.01
Est $0.01
-300.0%
Revenue
$21M
Est $23M
-10.9%
Q3 2025
Aug 11, 2025EPS
$0.01
Est $0.03
+60.0%
Revenue
$20M
Est $19M
+7.6%
Q2 2025
May 12, 2025EPS
$0.01
Est $0.04
+75.0%
Revenue
$22M
Est $21M
+1.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.01vs $0.35-102.9% | $24Mvs $23M+2.7% |
| Q4 2025 | Nov 6, 2025 | $0.01vs $0.01-300.0% | $21Mvs $23M-10.9% |
| Q3 2025 | Aug 11, 2025 | $0.01vs $0.03+60.0% | $20Mvs $19M+7.6% |
| Q2 2025 | May 12, 2025 | $0.01vs $0.04+75.0% | $22Mvs $21M+1.7% |
Based on last 12 quarters of dataView full earnings history →
HBIO Peer Comparison
Harvard Bioscience, Inc. (HBIO) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ITRN | 1.38B | 58.89 | 20.17 | 6.77% | 16.15% | 27.27% | 4.83% | 0.02 |
 BEAT | 34.34M | 0.86 | -1.38 | -5.71% | ||||
 MLAB | 585.38M | 105.96 | -294.32 | 11.47% | 1.51% | 2% | 7.23% | 1.14 |
 XPER | 752.09M | 6.90 | 6.97 | -10.19% | 25.05% | 23.11% | 20.78% | 0.06 |
 LMAT | 2.51B | 110.22 | 43.74 | 13.53% | 23.13% | 15.58% | 2.97% | 0.47 |
 WAT | 20.8B | 349.53 | 32.48 | 6.99% | 11.91% | 8.04% | 2.6% | 0.55 |
 TECH | 7.39B | 47.41 | 103.05 | 5.23% | 6.67% | 3.99% | 3.47% | 0.23 |
 BRKR | 6.42B | 42.30 | 55.66 | 13.56% | -0.25% | -0.34% | 2.12% | 1.24 |
Compare HBIO vs Peers
Harvard Bioscience, Inc. (HBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HBIO Income Statement
Harvard Bioscience, Inc. (HBIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 101.88M | 120.77M | 116.18M | 102.1M | 118.9M | 113.33M | 112.25M | 94.14M | 86.55M |
| Revenue Growth % | -2.52% | 18.54% | -3.81% | -12.12% | 16.46% | -4.68% | -0.96% | -16.14% | -8.06% |
| Cost of Goods Sold | 54.28M | 57.59M | 51.85M | 44.06M | 51.25M | 52.52M | 46.18M | 39.37M | 40.67M |
| COGS % of Revenue | 53.28% | 47.69% | 44.63% | 43.15% | 43.1% | 46.34% | 41.14% | 41.82% | 46.99% |
| Gross Profit | 47.6M▲ 0% | 63.18M▲ 32.7% | 64.32M▲ 1.8% | 58.04M▼ 9.8% | 67.65M▲ 16.6% | 60.82M▼ 10.1% | 66.07M▲ 8.6% | 54.77M▼ 17.1% | 45.88M▼ 16.2% |
| Gross Margin % | 46.72% | 52.31% | 55.37% | 56.85% | 56.9% | 53.66% | 58.86% | 58.18% | 53.01% |
| Gross Profit Growth % | -1.69% | 32.74% | 1.81% | -9.76% | 16.56% | -10.1% | 8.64% | -17.11% | -16.22% |
| Operating Expenses | 47.7M | 62.2M | 63.95M | 57.82M | 65.59M | 67.75M | 64.18M | 60.98M | 46.51M |
| OpEx % of Revenue | 46.82% | 51.5% | 55.04% | 56.63% | 55.16% | 59.78% | 57.17% | 64.78% | 53.74% |
| Selling, General & Admin | 39.61M | 45.83M | 46.02M | 43.42M | 48.95M | 49.53M | 46.89M | 43.7M | 36.96M |
| SG&A % of Revenue | 38.88% | 37.94% | 39.62% | 42.53% | 41.17% | 43.71% | 41.77% | 46.43% | 42.7% |
| Research & Development | 5.64M | 10.99M | 10.71M | 8.69M | 10.8M | 12.33M | 11.76M | 10.41M | 8.82M |
| R&D % of Revenue | 5.54% | 9.1% | 9.22% | 8.51% | 9.08% | 10.88% | 10.48% | 11.05% | 10.2% |
| Other Operating Expenses | -740K | -4.28M | 7.21M | 5.71M | 5.84M | 5.89M | 5.53M | 6.87M | 729K |
| Operating Income | -101K▲ 0% | 984K▲ 1074.3% | 377K▼ 61.7% | 221K▼ 41.4% | 2.07M▲ 834.8% | -6.93M▼ 435.6% | 1.89M▲ 127.3% | -6.21M▼ 427.9% | -629K▲ 89.9% |
| Operating Margin % | -0.1% | 0.81% | 0.32% | 0.22% | 1.74% | -6.12% | 1.69% | -6.6% | -0.73% |
| Operating Income Growth % | 96.63% | 1074.26% | -61.69% | -41.38% | 834.84% | -435.58% | 127.32% | -427.93% | 89.87% |
| EBITDA | 2.81M | 8.82M | 8.11M | 7.85M | 9.69M | 642K | 8.89M | 771K | 5.32M |
| EBITDA Margin % | 2.76% | 7.3% | 6.98% | 7.69% | 8.15% | 0.57% | 7.92% | 0.82% | 6.14% |
| EBITDA Growth % | 120.13% | 213.73% | -8.04% | -3.17% | 23.35% | -93.37% | 1285.05% | -91.33% | 589.49% |
| D&A (Non-Cash Add-back) | 2.91M | 7.83M | 7.73M | 7.63M | 7.62M | 7.58M | 7M | 6.98M | 5.95M |
| EBIT | -1.91M | -2.47M | -92K | -2.46M | 1.4M | -6.63M | 1.03M | -8.46M | -629K |
| Net Interest Income | -713K | -5.37M | -5.41M | -4.83M | -1.54M | -2.55M | -3.59M | -3.21M | -4.92M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 713K | 5.37M | 5.41M | 4.83M | 1.54M | 2.55M | 3.59M | 3.21M | 4.92M |
| Other Income/Expense | -1.99M | -8.96M | -5.88M | -7.51M | -2.21M | -2.25M | -4.45M | -5.45M | -56.76M |
| Pretax Income | -2.09M▲ 0% | -8.52M▼ 307.8% | -5.5M▲ 35.4% | -7.29M▼ 32.5% | -140K▲ 98.1% | -9.18M▼ 6456.4% | -2.56M▲ 72.2% | -11.66M▼ 356.4% | -57.39M▼ 392.0% |
| Pretax Margin % | -2.05% | -7.05% | -4.74% | -7.14% | -0.12% | -8.1% | -2.28% | -12.39% | -66.3% |
| Income Tax | -1.22M | -3.68M | -815K | 518K | 148K | 337K | 859K | 740K | -686K |
| Effective Tax Rate % | 58.57% | 43.17% | 14.81% | -7.1% | -105.71% | -3.67% | -33.61% | -6.34% | 1.2% |
| Net Income | -865K▲ 0% | -3.46M▼ 300.2% | -4.69M▼ 35.4% | -7.81M▼ 66.6% | -288K▲ 96.3% | -9.52M▼ 3204.2% | -3.42M▲ 64.1% | -12.4M▼ 263.3% | -56.7M▼ 357.1% |
| Net Margin % | -0.85% | -2.87% | -4.03% | -7.65% | -0.24% | -8.4% | -3.04% | -13.18% | -65.51% |
| Net Income Growth % | 79.92% | -300.23% | -35.38% | -66.63% | 96.31% | -3204.17% | 64.11% | -263.25% | -357.07% |
| Net Income (Continuing) | -2.02M | -4.3M | -4.69M | -7.81M | -288K | -9.52M | -3.42M | -12.4M | -56.7M |
| Discontinued Operations | 1.15M | 1.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.02▲ 0% | -0.10▼ 281.5% | -0.12▼ 26.3% | -0.20▼ 66.7% | -0.01▲ 96.5% | -0.23▼ 3139.4% | -0.08▲ 65.0% | -0.28▼ 247.8% | -1.28▼ 357.1% |
| EPS Growth % | 80.85% | -281.53% | -26.32% | -66.67% | 96.45% | - | 65% | -247.83% | -357.14% |
| EPS (Basic) | -0.03 | -0.10 | -0.12 | -0.20 | -0.01 | -0.23 | -0.08 | -0.28 | -1.28 |
| Diluted Shares Outstanding | 34.75M | 36.45M | 37.81M | 38.64M | 40.34M | 41.41M | 42.42M | 43.54M | 44.39M |
| Basic Shares Outstanding | 33.6M | 35.83M | 37.81M | 38.64M | 40.34M | 41.41M | 42.42M | 43.54M | 44.39M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
HBIO Balance Sheet
Harvard Bioscience, Inc. (HBIO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 47.53M | 54.72M | 53.57M | 51.7M | 61.58M | 51.12M | 49.04M | 45.12M | 48.23M |
| Cash & Short-Term Investments | 5.73M | 8.17M | 8.34M | 8.32M | 7.82M | 4.51M | 4.28M | 4.11M | 8.61M |
| Cash Only | 5.73M | 8.17M | 8.34M | 8.32M | 7.82M | 4.51M | 4.28M | 4.11M | 8.61M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 17.09M | 21.46M | 20.7M | 17.77M | 21.83M | 16.7M | 16.1M | 14.87M | 16.04M |
| Days Sales Outstanding | 61.23 | 64.86 | 65.05 | 63.51 | 67.02 | 53.8 | 52.35 | 57.64 | 67.66 |
| Inventory | 21.35M | 25.09M | 22.06M | 22.26M | 27.59M | 26.44M | 24.72M | 23.25M | 20.8M |
| Days Inventory Outstanding | 143.57 | 158.99 | 155.29 | 184.43 | 196.47 | 183.76 | 195.36 | 215.51 | 186.73 |
| Other Current Assets | 12.11M | 3.11M | 2.47M | 3.35M | 4.34M | 3.47M | 3.94M | 2.9M | 2.76M |
| Total Non-Current Assets | 61.82M | 113.35M | 111.3M | 104.55M | 100.76M | 94.24M | 88.33M | 81.53M | 31.85M |
| Property, Plant & Equipment | 4.14M | 5.9M | 13.24M | 11.72M | 10.31M | 9.18M | 8.75M | 11.24M | 4.79M |
| Fixed Asset Turnover | 24.61x | 20.48x | 8.78x | 8.71x | 11.53x | 12.34x | 12.82x | 8.38x | 18.08x |
| Goodwill | 39.97M | 57.3M | 57.38M | 58.59M | 57.69M | 56.26M | 57.06M | 56.32M | 9.56M |
| Intangible Assets | 17.2M | 45.76M | 38.41M | 33.15M | 27.39M | 21.01M | 16.04M | 11.13M | 7.64M |
| Long-Term Investments | 0 | -211K | 0 | 0 | 0 | 0 | 3.5M | 0 | 0 |
| Other Non-Current Assets | 324K | 4.92M | 2.27M | 1.09M | 5.38M | 7.78M | 2.97M | 2.83M | 9.86M |
| Total Assets | 109.35M▲ 0% | 168.07M▲ 53.7% | 164.87M▼ 1.9% | 156.25M▼ 5.2% | 162.34M▲ 3.9% | 145.36M▼ 10.5% | 137.37M▼ 5.5% | 126.64M▼ 7.8% | 80.07M▼ 36.8% |
| Asset Turnover | 0.93x | 0.72x | 0.70x | 0.65x | 0.73x | 0.78x | 0.82x | 0.74x | 1.08x |
| Asset Growth % | 1.47% | 53.7% | -1.91% | -5.23% | 3.9% | -10.46% | -5.5% | -7.81% | -36.77% |
| Total Current Liabilities | 14.04M | 21.51M | 25.31M | 21.05M | 25.32M | 23.25M | 26.54M | 54.96M | 21.96M |
| Accounts Payable | 4.41M | 7.36M | 5.34M | 5.97M | 4.91M | 6.45M | 5.55M | 4.79M | 0 |
| Days Payables Outstanding | 29.65 | 46.64 | 37.58 | 49.47 | 34.97 | 44.81 | 43.9 | 44.38 | - |
| Short-Term Debt | 2.77M | 2M | 6.9M | 1.72M | 3.23M | 3.81M | 5.86M | 36.96M | 0 |
| Deferred Revenue (Current) | 633K | 4.19M | 3.95M | 3.77M | 4.27M | 3.37M | 0 | 3.81M | 0 |
| Other Current Liabilities | 3.61M | 4.45M | 5.67M | 7.15M | 10.54M | 7.49M | 13.71M | 8.25M | 21.96M |
| Current Ratio | 3.39x | 2.54x | 2.12x | 2.46x | 2.43x | 2.20x | 1.85x | 0.82x | 2.20x |
| Quick Ratio | 1.86x | 1.38x | 1.24x | 1.40x | 1.34x | 1.06x | 0.92x | 0.40x | 1.25x |
| Cash Conversion Cycle | 175.15 | 177.22 | 182.75 | 198.46 | 228.51 | 192.75 | 203.81 | 228.77 | - |
| Total Non-Current Liabilities | 14.41M | 64.38M | 57.86M | 58.52M | 53.63M | 49.89M | 37.75M | 8.35M | 44.38M |
| Long-Term Debt | 8.98M | 58.8M | 46.92M | 46.29M | 45.09M | 43.01M | 30.7M | 0 | 6.88M |
| Capital Lease Obligations | 0 | 0 | 8.22M | 7.48M | 6.49M | 5.28M | 4.79M | 6.38M | 0 |
| Deferred Tax Liabilities | 3.96M | 2.3M | 1.97M | 1.9M | 1.56M | 590K | 776K | 710K | 317K |
| Other Non-Current Liabilities | 5.43M | 3.29M | 749K | 2.85M | 486K | 1.01M | 1.48M | 1.25M | 37.18M |
| Total Liabilities | 28.45M | 85.89M | 83.18M | 79.57M | 78.94M | 73.14M | 64.29M | 63.3M | 66.34M |
| Total Debt | 11.75M | 60.8M | 64.47M | 57.6M | 56.96M | 54.24M | 42.77M | 44.49M | 35.87M |
| Net Debt | 6.01M | 52.62M | 56.13M | 49.28M | 49.14M | 49.73M | 38.49M | 40.39M | 27.26M |
| Debt / Equity | 0.15x | 0.74x | 0.79x | 0.75x | 0.68x | 0.75x | 0.59x | 0.70x | 2.61x |
| Debt / EBITDA | 4.18x | 6.89x | 7.95x | 7.33x | 5.88x | 84.49x | 4.81x | 57.71x | 6.75x |
| Net Debt / EBITDA | 2.14x | 5.97x | 6.92x | 6.28x | 5.07x | 77.47x | 4.33x | 52.38x | 5.13x |
| Interest Coverage | -0.14x | 0.18x | 0.07x | 0.05x | 1.34x | -2.72x | 0.53x | -1.94x | -0.13x |
| Total Equity | 80.9M▲ 0% | 82.18M▲ 1.6% | 81.69M▼ 0.6% | 76.68M▼ 6.1% | 83.4M▲ 8.8% | 72.22M▼ 13.4% | 73.07M▲ 1.2% | 63.34M▼ 13.3% | 13.73M▼ 78.3% |
| Equity Growth % | 12.06% | 1.59% | -0.6% | -6.14% | 8.76% | -13.41% | 1.18% | -13.32% | -78.32% |
| Book Value per Share | 2.33 | 2.25 | 2.16 | 1.98 | 2.07 | 1.74 | 1.72 | 1.45 | 0.31 |
| Total Shareholders' Equity | 80.9M | 82.18M | 81.69M | 76.68M | 83.4M | 72.22M | 73.07M | 63.34M | 13.73M |
| Common Stock | 419K | 436K | 438K | 444K | 452K | 454K | 434K | 441K | 447K |
| Retained Earnings | -116.97M | -119.89M | -124.58M | -132.39M | -132.67M | -142.19M | -145.6M | -158.01M | -214.71M |
| Treasury Stock | -10.67M | -10.67M | -10.67M | -10.67M | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -10.68M | -13.53M | -12.69M | -13.07M | -10.03M | -15.05M | -14.19M | -15.67M | -11.67M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HBIO Cash Flow Statement
Harvard Bioscience, Inc. (HBIO) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 1.06M | 2.34M | 8.05M | 9.33M | 1.26M | 1.15M | 14.03M | 1.44M | 6.73M |
| Operating CF Margin % | 1.04% | 1.94% | 6.93% | 9.14% | 1.06% | 1.02% | 12.5% | 1.53% | 7.77% |
| Operating CF Growth % | -80.36% | 121.76% | 243.3% | 15.96% | -86.48% | -8.72% | 1117.71% | -89.73% | 367.29% |
| Net Income | -865K | -3.46M | -4.69M | -7.81M | -288K | -9.52M | -3.42M | -12.4M | -56.7M |
| Depreciation & Amortization | 3.8M | 7.88M | 7.73M | 7.63M | 7.62M | 7.58M | 7M | 7.16M | -4.93M |
| Stock-Based Compensation | 3.5M | 3.04M | 3.03M | 3.65M | 4.17M | 4.41M | 5M | 4.34M | -1.67M |
| Deferred Taxes | -1.58M | -2.86M | -398K | -143K | -330K | -414K | 336K | 363K | 50K |
| Other Non-Cash Items | 16K | -584K | 2.32M | 1.9M | 280K | -3.62M | 509K | 1.92M | 76.28M |
| Working Capital Changes | -3.81M | -1.68M | 42K | 4.11M | -10.19M | 2.72M | 4.6M | 65K | -6.3M |
| Change in Receivables | 196K | -2.79M | 468K | 3.1M | -4.29M | 4.78M | 810K | 974K | -4.67M |
| Change in Inventory | -548K | 2.55M | 3.26M | 413K | -5.86M | 252K | 1.52M | -64K | -2.32M |
| Change in Payables | -918K | 1.59M | -2.05M | 511K | 0 | -1.4M | -523K | -1.78M | 0 |
| Cash from Investing | -917K | -53.26M | -229K | -1.4M | -1.34M | -1.59M | -1.8M | -1.34M | -1.86M |
| Capital Expenditures | -890K | -986K | -1.22M | -1.15M | -1.2M | -1.59M | -1.79M | -2.64M | -1.26M |
| CapEx % of Revenue | 0.87% | 0.82% | 1.05% | 1.13% | 1% | 1.4% | 1.59% | 2.81% | 1.45% |
| Acquisitions | 12K | -52.25M | 1M | 0 | 0 | 0 | 512K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -27K | -16K | -15K | -250K | -150K | 0 | -523K | -619K | -605K |
| Cash from Financing | -1.79M | 53.05M | -7.63M | -7.97M | -252K | -2.84M | -12.13M | -131K | -1.29M |
| Debt Issued (Net) | -1.95M | 50.5M | -7.4M | -6.89M | 50K | -1.79M | -10.54M | 227K | -1.18M |
| Equity Issued (Net) | 160K | 1000K | -221K | -1000K | 0 | -1000K | 0 | 0 | 47K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -221K | -1.14M | 0 | -1.63M | 0 | 0 | 0 |
| Other Financing | 0 | -2.01M | -2K | 70K | -302K | 577K | -1.59M | -358K | -156K |
| Net Change in Cash | 137K▲ 0% | 2.44M▲ 1681.0% | 162K▼ 93.4% | -18K▼ 111.1% | -496K▼ 2655.6% | -3.31M▼ 567.9% | -225K▲ 93.2% | -175K▲ 22.2% | 4.51M▲ 2674.9% |
| Free Cash Flow | 167K▲ 0% | 1.36M▲ 713.2% | 6.83M▲ 403.0% | 8.18M▲ 19.7% | -83K▼ 101.0% | -438K▼ 427.7% | 11.72M▲ 2775.1% | -1.82M▼ 115.6% | 5.62M▲ 408.0% |
| FCF Margin % | 0.16% | 1.12% | 5.88% | 8.01% | -0.07% | -0.39% | 10.44% | -1.94% | 6.49% |
| FCF Growth % | -95.72% | 713.17% | 403.02% | 19.73% | -101.01% | -427.71% | 2775.11% | -115.56% | 408.01% |
| FCF per Share | 0.00 | 0.04 | 0.18 | 0.21 | -0.00 | -0.01 | 0.28 | -0.04 | 0.13 |
| FCF Conversion (FCF/Net Income) | -1.22x | -0.68x | -1.72x | -1.19x | -4.38x | -0.12x | -4.11x | -0.12x | -0.12x |
| Interest Paid | 686K | 4.99M | 5.5M | 4.88M | 1.58M | 2.31M | 3.79M | 3.23M | 0 |
| Taxes Paid | -13K | 98K | 374K | 416K | 577K | 534K | 207K | 0 | 0 |
HBIO Key Ratios
Harvard Bioscience, Inc. (HBIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -5.75% | -1.13% | -4.25% | -5.72% | -9.86% | -0.36% | -12.23% | -4.7% | -18.19% | -147.13% |
| Return on Invested Capital (ROIC) | -2.64% | -0.09% | 0.67% | 0.21% | 0.13% | 1.2% | -4.09% | 1.22% | -4.33% | -0.65% |
| Gross Margin | 46.32% | 46.72% | 52.31% | 55.37% | 56.85% | 56.9% | 53.66% | 58.86% | 58.18% | 53.01% |
| Net Margin | -4.12% | -0.85% | -2.87% | -4.03% | -7.65% | -0.24% | -8.4% | -3.04% | -13.18% | -65.51% |
| Debt / Equity | 0.19x | 0.15x | 0.74x | 0.79x | 0.75x | 0.68x | 0.75x | 0.59x | 0.70x | 2.61x |
| Interest Coverage | -4.67x | -0.14x | 0.18x | 0.07x | 0.05x | 1.34x | -2.72x | 0.53x | -1.94x | -0.13x |
| FCF Conversion | -1.25x | -1.22x | -0.68x | -1.72x | -1.19x | -4.38x | -0.12x | -4.11x | -0.12x | -0.12x |
| Revenue Growth | -3.81% | -2.52% | 18.54% | -3.81% | -12.12% | 16.46% | -4.68% | -0.96% | -16.14% | -8.06% |
HBIO SEC Filings & Documents
Harvard Bioscience, Inc. (HBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
HBIO Frequently Asked Questions
Harvard Bioscience, Inc. (HBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Harvard Bioscience, Inc. (HBIO) reported $86.5M in revenue for fiscal year 2025. This represents a 612% increase from $12.2M in 1998.
Harvard Bioscience, Inc. (HBIO) saw revenue decline by 8.1% over the past year.
Harvard Bioscience, Inc. (HBIO) reported a net loss of $56.7M for fiscal year 2025.
Dividend & Returns
Harvard Bioscience, Inc. (HBIO) has a return on equity (ROE) of -147.1%. Negative ROE indicates the company is unprofitable.
Harvard Bioscience, Inc. (HBIO) generated $5.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More HBIO
Harvard Bioscience, Inc. (HBIO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates